BARHL2 Human Pre-designed siRNA Set A

Cat. No.: B1479828

Storage

Store at -20°C

Shipped In

Ice chest + Ice pads

Panoramica

BARHL2 Human Pre-designed siRNA Set A contains three designed siRNAs for BARHL2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components BARHL2 siRNA-1: 5 nmol (HPLC) BARHL2 siRNA-2: 5 nmol (HPLC) BARHL2 siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 nmol (HPLC) FAM-labeled siRNA Negative Control: 5 nmol (HPLC) GAPDH siRNA Positive Control:5 nmol (HPLC)

Specifications

Condizioni di conservazione di stoccaggio

Store at -20°C

Spedito in

Ice chest + Ice pads

Questo prodotto richiede spedizione a catena fredda. I servizi di terra e altri servizi economici non sono disponibili.

Product Line

Prodotti biologici

Application Protocols

Item-specific information

• Tested applications, recommended transfection reagents, working concentrations, and step‑by‑step protocols are not specified for this item; refer to the CoA/Spec Sheet and SDS.

Notes

• Because no application protocol details are provided in the product data, users should follow their preferred transfection reagent’s protocol and standard RNAi best practices for optimization in the chosen cell model.

Biological Roles

Item-specific focus

• Target gene: BARHL2 (human). This siRNA set is designed to reduce BARHL2 expression for research applications.

General/literature background on BARHL2 (not product specifications)

• BARHL2 encodes a BarH‑like homeobox transcription factor implicated in neural development and patterning. BARHL family proteins typically function in cell fate specification by regulating transcriptional programs.
• Expression: Reported in developing central nervous system regions; expression can be context‑dependent and species‑specific.
• Functional themes: Regulation of differentiation markers, neuronal subtype specification, and coordination with other developmental transcription factors. Downstream effects are highly model‑dependent.

Research utility of BARHL2 knockdown (literature)

• Dissection of developmental pathways: Use siRNA‑mediated knockdown to map gene regulatory networks and identify BARHL2 targets by RNA‑seq/ChIP.
• Phenotypic probing: Evaluate consequences for neurite formation, migration, and lineage marker expression in human neural progenitors or iPSC‑derived neurons.
• Redundancy and compensation: Assess potential compensatory regulation by related homeobox factors via combinatorial perturbations.

Notes

• All biological roles above are literature context and may vary by cell type and experimental conditions.
• This product is for research use only; no clinical or diagnostic claims are made.

Buffer Applications

Applicability

• This product is an siRNA reagent and not itself a buffer. However, buffer selection is important for reconstitution, storage, and transfection workflows.

General/literature guidance (not item specifications)

• Reconstitution: RNase‑free water or TE buffer (10 mM Tris‑HCl, 0.1–1 mM EDTA, pH 7.5–8.0). EDTA helps chelate divalent cations that catalyze RNA degradation.
• Working dilutions: Prepare in nuclease‑free water or serum‑free medium during complexation with transfection reagents; avoid phosphate/EDTA during complex formation if incompatible with the delivery chemistry.
• pH range: Near neutral (pH 7.2–7.6) is typical for cell culture applications.
• Additives: RNase inhibitors are generally unnecessary for short handling times but may be used in sensitive workflows.

Not specified for this item

• Exact buffer composition provided by the manufacturer, if any, and recommended reconstitution concentration are not specified; refer to the CoA/Spec Sheet.

Green Alternatives

Context

• For siRNA reagents, “green chemistry” focuses on minimizing cold‑chain footprint, reducing single‑use plastics, and avoiding hazardous additives rather than replacing a solvent/chemical.

Practices and alternatives (general guidance)

• Format selection: Lyophilized shipments (when offered) reduce mass/volume and cold‑chain load relative to bulk aqueous solutions. For this item, format is not specified.
• Buffer choices: Use nuclease‑free water or low‑salt TE; avoid DEPC‑treated water disposal issues by procuring certified RNase‑free water.
• Transfection reagents: Consider biodegradable or less cytotoxic delivery systems to reduce waste and improve cell viability (e.g., lipid formulations with reduced PFAS content, polymer systems with degradable backbones). Selection is application‑specific.
• Scaling: Plan experiments to minimize excess thaw/freeze cycles and reduce wasted aliquots; this both improves data quality and reduces consumables.
• Waste management: Segregate plastic tips/tubes from general waste where recycling streams exist for clean polypropylene; neutralize and dispose of nucleic acid dyes/ethidium bromide alternatives responsibly.

Comparison snapshot (literature; not item‑specific)

• Lyophilized siRNA vs aqueous stocks: lower shipping weight/energy; requires careful reconstitution vs ready‑to‑use convenience.
• TE buffer vs PBS for storage: TE improves nuclease stability; PBS is simpler but may be less protective—no hazardous constituents in either case.

Note

• Specific environmental attributes of this product are not specified; refer to supplier documentation for packaging and format details.

Pharmaceutical Uses

Applicability

• This listing is a research‑grade siRNA set. It is not presented as a GMP material, excipient, or active pharmaceutical ingredient.

Statement

• For research use only. Not for human or veterinary use, not for clinical diagnostics, and not for therapeutic applications.

General context (literature; not item‑specific)

• In pharmaceutical R&D settings, research‑grade siRNAs are used for target validation, pathway deconvolution, and mechanism studies in preclinical models and in vitro systems.
• Transition to clinical development requires GMP manufacturing, extensive characterization (identity, purity, potency, stability, endotoxin/bioburden), and regulatory filings—none of which are implied by this product data.

Item-specific

• No pharmacopeial status, excipient roles, or GMP attributes are specified for this item.

Physical Properties

Item-specific facts (from Product Data)

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.

General/literature properties for siRNA (context; not item specifications)

• Typical length: 19–23 bp duplex with 2‑nt 3′ overhangs; approximate MW often 12–15 kDa per duplex depending on sequence and modifications.
• Physical state: supplied lyophilized or in aqueous, nuclease‑free buffer; hygroscopic, water‑soluble due to polyanionic backbone.
• Solubility: readily soluble in RNase‑free water, TE buffer (10 mM Tris, 0.1–1 mM EDTA, pH 7.5–8.0), and most physiological buffers; insoluble in organic solvents.
• pKa/logP: not directly applicable for polyanionic oligonucleotides; behavior dominated by multiple phosphate groups (always deprotonated at biological pH).
• UV absorbance (literature): strong at 260 nm; typical duplex extinction coefficients depend on sequence (ε260 commonly in the 200–300 k L·mol⁻1·cm⁻1 range for ~21‑mer duplexes). Exact ε for this item is not specified.
• Thermal behavior: duplex melting temperature (Tm) depends on length, GC content, salt; commonly 60–85°C for 21‑mers in physiological salt, but sequence‑specific.

Important

• Do not treat any of the above as specifications for this item. For exact concentration, extinction coefficient, buffer composition, and format, refer to the CoA/Spec Sheet.

Quality and Grades

Item-specific facts (from Product Data)

• Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet.

How to interpret grades for siRNA (general guidance; not item‑specific)

• Desalted vs. HPLC‑purified: HPLC purification reduces truncated sequences and improves knockdown consistency; PAGE can provide highest length homogeneity for very short duplexes.
• Duplex annealing quality: Verified duplexing (equimolar sense/antisense) and endotoxin testing are important for sensitive cell types.
• Residual salts/solvents: Low residual salts and absence of organic solvents improve transfection performance.
• QC metrics often provided: MALDI‑TOF/ESI mass confirmation, analytical HPLC purity, OD260, concentration, strand stoichiometry, endotoxin level, residual solvents/metals (where applicable).
• Stabilizers/modifications: 2′‑OMe, 2′‑F, phosphorothioate linkages, and overhang composition can enhance nuclease resistance and RISC loading; any such features for this item are not specified.

What is specific to this listing

• Pre‑designed set targeting human BARHL2. Exact sequence(s), purification level, and QC metrics are not specified for this item; consult the CoA/Spec Sheet for definitive details.

Reaction and Applications

Item-specific scope

• “Pre‑designed siRNA Set A” targeting human BARHL2 for RNA interference (RNAi) experiments. No further application details were provided; use cases below are general for siRNA targeting transcription factors.

General/literature applications of siRNA (not item specifications)

• Gene silencing: Transient knockdown of BARHL2 mRNA via RISC‑mediated cleavage of complementary transcripts in human cells.
• Functional genomics: Probe BARHL2 roles in developmental transcriptional programs, differentiation, or lineage specification by measuring downstream gene expression changes.
• Pathway mapping: Combine with RNA‑seq, qPCR, ChIP‑qPCR/ATAC‑seq to dissect transcriptional networks influenced by BARHL2.
• Phenotypic assays: Assess effects on proliferation, neurite outgrowth, cell fate markers in relevant human cell models; co‑transfect rescue constructs to verify on‑target effects.
• Combinatorial knockdowns: Use with siRNAs against cofactors to explore redundancy/epistasis.

Practical tips (literature)

• Use multiple independent siRNA duplexes (sets) to strengthen on‑target conclusions and mitigate off‑target artifacts.
• Include non‑targeting negative controls and positive control siRNA (e.g., PLK1 in cycling cells) to benchmark transfection efficiency.
• Titrate dose (e.g., 5–50 nM) and assess knockdown at 24–96 h, depending on mRNA/protein half‑life.
• Validate with orthogonal methods (qPCR for mRNA, immunoblot/IF for protein). Rescue with siRNA‑resistant BARHL2 cDNA where feasible.

Item-specific caution

• Sequence, chemical modifications, and recommended transfection conditions are not specified; consult the CoA/Spec Sheet.

Reaction Conditions

Applicability

• “Reaction conditions” are interpreted here as general transfection/use conditions for siRNA in cells. The following are literature‑based guidelines and not specifications for this item.

General guidance (literature)

• Cell density: Plate cells to reach 40–70% confluence at transfection time for adherent lines; optimize per cell type.
• Dose: Common starting range 5–50 nM siRNA duplex final concentration; titrate to minimize off‑target effects while maintaining knockdown.
• Complexation: Mix siRNA with cationic lipid/polymer in serum‑free medium; incubate 5–20 min at room temperature before adding to cells. Volumes and ratios are transfection reagent‑specific.
• Incubation: Replace with complete medium after 4–6 h if the reagent requires; otherwise add directly to complete medium per vendor guidance.
• Timelines: Maximal mRNA knockdown often within 24–48 h; protein reduction may lag (48–96 h) depending on protein half‑life.
• Controls: Non‑targeting siRNA, positive control siRNA, mock transfection, and dose‑response controls. Include cytotoxicity assessment (e.g., CellTiter‑Glo).
• Readouts: qPCR for BARHL2 mRNA, western blot/IF for BARHL2 protein if validated antibodies are available; RNA‑seq for global effects.

Item-specific

• No manufacturer‑provided conditions were specified for this item; consult the CoA/Spec Sheet and your transfection reagent documentation.

Safety and Handling

Item-specific facts (from Product Data)

• GHS classification, pictograms, signal word, and H‑statements: Not specified for this item; consult the SDS for authoritative safety information.
• Storage conditions: Store at −20°C.
• Shipping: Ice chest + ice pads.

General guidance for siRNA handling (literature/best practice)

• Typical hazards: Synthetic oligoribonucleotides are generally regarded as low hazard; nonetheless, handle as laboratory chemicals. Avoid inhalation of powders/aerosols and contact with eyes/skin.
• PPE: Laboratory coat, gloves (nitrile), and safety glasses. Use RNase‑free technique to prevent degradation.
• Incompatibilities: RNases (ubiquitous protein contaminants); avoid contact with non‑sterile plastics, unfiltered airflows, and shared solutions. Avoid strong acids/bases and nuclease‑contaminated reagents.
• First aid (overview): If inhaled, move to fresh air; for skin/eye contact, rinse with water for ≥15 minutes; if ingested, rinse mouth with water. Seek medical attention as needed. Follow SDS guidance.
• Engineering controls: Work in a clean area; for sterile or cell culture applications, use a biosafety cabinet (Class II) and nuclease‑free consumables.
• Waste: Dispose of aqueous nucleic acid waste according to institutional biosafety/chemical waste practices; no special decomposition hazards are typical for oligonucleotides.

Notes

• Always defer to the product SDS for hazard classification, first‑aid, firefighting, spill response, and transport information.

Solvent Selection

Applicability

• This product is an siRNA reagent, not a solvent. Classic “solvent selection” does not apply. Instead, reconstitution and working buffer choice are critical.

General/literature guidance for siRNA dissolution (not item specifications)

• Primary solvent: RNase‑free water is the default for initial dissolution.
• Storage buffer: TE (10 mM Tris‑HCl, 0.1–1 mM EDTA, pH 7.5–8.0) is commonly used to chelate divalent cations that catalyze RNA degradation.
• Working buffer: For transfection, dilute into serum‑free medium during complexation with lipid/polymer, then add to cells in complete medium per transfection reagent instructions.
• Ionic strength/pH: Physiological pH 7.2–7.6; monovalent salts (Na+, K+) stabilize duplexes; Mg2+ can promote folding/aggregation—optimize per cell line.

Comparison notes (literature)

• RNase‑free water vs TE: water maximizes flexibility; TE improves stability for long‑term frozen stocks. EDTA can interfere with some cationic delivery systems—use low EDTA (0.1 mM) or water for complexation.
• PBS: Suitable for short handling but phosphate can interact with some transfection reagents; follow reagent manufacturer guidance.

Item-specific

• Exact recommended reconstitution buffer and concentration are not specified for this item; refer to the CoA/Spec Sheet.

Storage and Reconstitution

Item-specific facts (from Product Data)

• Storage conditions: Store at −20°C.
• Shipped in: Ice chest + ice pads.

Not specified for this item; refer to CoA/Spec Sheet

• Supplied format (lyophilized vs aqueous), initial concentration, buffer composition, recommended aliquot size, freeze–thaw tolerance, and shelf life.

General/literature guidance (not specifications)

• Upon receipt: Inspect cold‑chain integrity. If lyophilized, briefly centrifuge before opening to collect material.
• Reconstitution: Dissolve in RNase‑free water or TE buffer to a convenient stock (e.g., 10–50 µM), mix gently, avoid vigorous vortexing that can shear.
• Aliquoting: Prepare single‑use aliquots to minimize freeze–thaw cycles. Store working stocks at −20°C; for longer term, −80°C is common.
• Handling: Use RNase‑free plasticware and filtered tips; keep on ice during setup. Thaw on ice, mix by gentle flick/low‑speed spin.
• Stability: Avoid repeated freeze–thaw; protect from nucleases and prolonged ambient temperatures.

Reminder

• Follow the product CoA/Spec Sheet for any item‑specific instructions that supersede the general practices above.

Structure and Identity

Item-specific facts (from Product Data)

• Product: BARHL2 Human Pre-designed siRNA Set A (SKU: B1479828)
• Format/Type: Small interfering RNA (siRNA) reagent set targeting human BARHL2 mRNA
• Intended use: For research use only
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• CAS, CID, InChIKey, SMILES: Not applicable/not specified for siRNA reagents in this listing.

General/literature description of structure (for siRNA)

• siRNA is typically a short, double‑stranded RNA duplex (commonly 19–23 base pairs) with 2‑nt 3′ overhangs on each strand.
• Composed of ribonucleotides linked by 3′→5′ phosphodiester bonds; strands are sense (passenger) and antisense (guide) complementary to the target mRNA.
• Structural features: anionic phosphate backbone, multiple hydrogen‑bonding donors/acceptors via Watson–Crick base pairs (A:U and G:C), and potential chemical stabilizations (e.g., 2′‑OMe, phosphorothioate) may be used in some designs (modifications for this item are not specified).
• 2D description: two antiparallel, complementary single strands annealed to form a short A‑form duplex with sticky 3′ overhangs; no covalent rings except ribose furanose rings; no stereocenters beyond natural ribose configurations.

Notes

• Specific sequence, length, strand stoichiometry, overhang identity, and any chemical modifications are not specified for this item; refer to the product CoA/Spec Sheet for exact design.

Synthetic Utility

Scope

• As a biological reagent (siRNA), this product is not a building block or reagent for small‑molecule synthesis. Traditional organic synthetic utility does not apply.

Research utility (literature; not item‑specific)

• Functional genomics tool: Enables targeted, sequence‑specific post‑transcriptional gene silencing to probe BARHL2 function.
• Screening: Use in arrayed or pooled knockdown experiments to identify phenotypes and genetic interactions.
• Validation cascade: Pair with CRISPRi/CRISPR KO to orthogonally confirm gene function; siRNA provides rapid, reversible perturbation complementary to genome editing.

Best practices

• Use multiple independent duplexes and maintain consistent transfection conditions across experiments to allow quantitative comparisons.

Item-specific

• Exact sequence composition, modifications, and purification—key determinants of performance—are not specified; refer to CoA/Spec Sheet.

Target Specificity

Item-specific facts (from Product Data)

• Target: BARHL2 (BarH‑like homeobox 2)
• Species: Human
• Format: Pre‑designed siRNA Set A (multiple duplexes typically designed against distinct regions of the same transcript; exact count and sequences are not specified for this item)

Not specified for this item; refer to CoA/Spec Sheet

• Specific siRNA sequences and target exon/UTR regions
• Predicted off‑target analysis and seed region annotations
• Any chemical modifications used to enhance specificity or stability

General/literature notes on siRNA specificity

• Specificity is primarily determined by perfect complementarity of the antisense (guide) strand to the target mRNA. Seed‑region (nt 2–8) complementarity can cause microRNA‑like off‑targets.
• Using pools of independent siRNAs against the same gene and demonstrating convergent phenotypes strengthens on‑target attribution.
• Mismatch controls, rescue with siRNA‑resistant cDNA, and transcriptome profiling are standard approaches to validate specificity.

Domande frequenti

How should this product be stored?

Store at ?20 °C. Freezer storage is required to maintain the specified shelf life.

How is this product shipped?

This product ships in an insulated container with ice pads. Unpack on arrival and transfer it to the storage condition stated above.

What documentation is provided?

Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.